Research & Morphogenic Alliances

Research Alliances

Over the years, we have proudly partnered with several world-class research institutions, allowing for continued progress and advancements within the field of morphogenics.

Areva Med

  • Collaboration Agreement, 2016

Mayo Clinic

  • Collaboration Agreement, 2016

University of Wisconsin-Madison

  • Collaboration Agreement, 2015

Biocare Medical LLC

  • License and Collaboration Agreement, 2015

University of Gothenburg

  • Collaboration Agreement, 2015

Blaze Bioscience, Inc.

  • License Agreement, 2015

Sorrento Therapeutics

  • Research Option Agreement, 2014

Stealth Biologics

  • Research Collaboration, 2014

Biocare Medical

  • License Agreement, 2012

Fox Chase Cancer Center

  • Sponsored Research Collaboration, 2012

Hokkaido University

  • Sponsored Research Agreement, 2010

Centocor Ortho Biotech Inc.

  • License Agreement for an Antibody, 2009

Human Genome Sciences

  • Collaboration Agreement, 2009

University Hospital Heidelberg

  • Research Collaboration, 2009
  • Develop antibodies to cancer targets

Human Monoclonals International

  • Exclusive License Agreement, 2008
  • Morphotek to develop a lead human antibody to a cancer antigen developed by HMI

National Institute of Allergy and Infectious Disease

  • Research collaboration, 2008
  • Morphotek to develop human antibodies to infectious disease pathogens and NIAID researchers will validate therapeutic activity

John Wayne Cancer Institute

  • Research Collaboration, 2005
  • Morphotek and JWCI to develop antibodies to treat melanoma and lung cancer

John Hopkins University

  • Exclusive Technology License Agreement, 2000
  • Cornerstone patent that helped launch the company

Ludwig Institute for Cancer Research

  • Exclusive License Agreements, 2002 and 2004
  • Morphotek obtained exclusive rights to MORAb-003 and MORAb-004; two therapeutic monoclonal antibodies targeting antigens over-expressed in various cancers.
  • Research Collaboration, 2008
  • Ludwig will use proprietary systems to validate tumor targets

National Cancer Institute

  • Cooperative Research and Development Agreement, 2004
  • Exclusive License Agreement, 2005
  • Morphotek obtained exclusive rights to MORAb-009; a monoclonal antibody targeting a glycoprotein over-expressed in pancreatic and ovarian cancers and mesotheliomas.
  • Research Collaboration, 2008
  • Develop and Validate Two Antibodies to Two Independent Prostate Cancer Targets

Pennsylvania State University

  • Research Agreement, 2011
  • Support research to validate targets expressed in hypoxic regions of tumors and therapeutic antibodies directed at hypoxic patients

United States Army Medical Research Institute of Infectious Diseases

  • Cooperative Research and Development Agreement, 2004
  • Morphotek to develop biomolecules that kill pathogenic microbes and fully human monoclonal antibodies that protect against the toxic effects of pathogenic antigens being developed for biological warfare

United States Department of Defense

  • Cooperative Research and Development Agreement, 2005
  • Morphotek to develop fully human, high-affinity, antibodies that can serve as biosensors for the early detection of pathogenic agents, as well as be developed as drugs for the treatment of individuals at risk for exposure to biological warfare agents.

Wistar Institute

  • Research Collaboration Agreement, 2002
  • Morphotek applied its proprietary MORPHODOMA® technology to create optimized hybridoma cell lines for Wistar

Partnership News

December 11, 2017

Morphotek and Rockefeller University Form a Sponsored Research Agreement to Study the Immunosuppressive Effects of the Tumor Shed Antigen CA125 and its Potential Impact in Future Patient Therapies
Read More

September 6, 2017

Morphotek Announces Collaboration Agreement with the Johns Hopkins University to Research and Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens
Read More

September 5, 2017

Morphotek, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc to Commercialize the CA125 II Assay as A Companion Diagnostic for Farletuzumab
Read More

October 3, 2016

Morphotek and Eurofarma Laboratorios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America
Read More

September 13, 2016

Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center to Study Immunosuppressive Effects of Tumor Shed Antigens to Improve Future Patient Therapies
Read More

March 31, 2016

Morphotek and AREVA Med to collaborate on Lead-212 Targeted Alpha Therapies
Read More

February 3, 2016

Morphotek Announces Collaboration with Mayo Clinic
Read More

December 16, 2015

Morphotek, Inc. Announces an Agreement With Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Mesothelin in Malignant Tissues
Read More

December 3, 2015

Morphotek Announces Collaboration Agreement with University of Wisconsin-Madison to Study the Immunosuppressive Effects of CA125 Tumor Antigen on Immune-Based Therapies for Ovarian Cancer
Read More

November 17, 2015

Morphotek Announces Collaboration Agreement With University of Gothenburg to Develop Farletuzumab, an Investigational Anti-Folate Receptor Alpha Monoclonal Antibody, for Alpha-Particle Radioimmunotherapy in Ovarian Cancer
Read More

Displaying results 1-10 (of 17)
 |<  < 1 - 2  >  >|